Premium
Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk‐index score with procalcitonin, C‐reactive protein, serum amyloid A, and interleukins‐1β, ‐6, ‐8 and ‐10
Author(s) -
UYS A.,
RAPOPORT B.L.,
FICKL H.,
MEYER P.W.A.,
ANDERSON R.
Publication year - 2007
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2007.00780.x
Subject(s) - procalcitonin , medicine , cancer , c reactive protein , febrile neutropenia , oncology , serum amyloid a , neutropenia , gastroenterology , inflammation , chemotherapy , sepsis
The primary objective of the study was to compare the predictive potential of procalcitonin (PCT), C‐reactive protein (CRP), serum amyloid A (SAA), and interleukin (IL)‐1β, IL‐6, IL‐8, and IL‐10, with that of the Multinational Association of Supportive Care in Cancer (MASCC) risk‐index score in cancer patients on presentation with chemotherapy‐induced febrile neutropenia (FN). Seventy‐eight consecutive FN episodes in 63 patients were included, and MASCC scores, as well as concentrations of CRP, SAA, PCT, and IL‐1β, IL‐6, IL‐8 and IL‐10, and haematological parameters were determined on presentation, 72 h later and at outcome. Multivariate analysis of data revealed the MASCC score, but none of the laboratory parameters, to be an accurate, independent variable ( P < 0.0001) for prediction of resolution with or without complications and death. Of the various laboratory parameters, PCT had the strongest association with the MASCC score ( r = −0.51; P < 0.0001). In cancer patients who present with FN, the MASCC risk‐index score is a useful predictor of outcome, while measurement of PCT, CRP, SAA, or IL‐1β, IL‐6, IL‐8 and IL‐10, is of limited value.